Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Following subcutaneous administration in clinical models: Both components demonstrate prolonged absorption with peak plasma concentrations occurring 24-72 hours post-injection GLP3 exhibits approximately 6-day half-life enabling once-weekly dosing Cagrilintide demonstrates 120-165 hour half-life (5-7 days) suitable for weekly administration Lipid conjugation of both peptides enables albumin binding and extended systemic circulation Distribution patterns show systemic exposure with concentration in metabolically active tissues The fatty diacid modifications on both peptides (C20 for GLP3 , eicosanedioic acid for cagrilintide) serve as albumin-binding moieties that dramatically extend plasma residence time compared to native peptides
10.3389/fimmu.2025.1521554 102 ZhangB.DaiC.JiangJ.WangJ.YangY.FengJ
Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus
Portrait offers strategic expertise to help you make informed decisions and achieve long-term success
doi:10.2164/jandrol.111.013961
US$ 27.49
US$ 27.86
US$ 27.00
US$ 22.74
US$ 22.65
